期刊文献+

基于高通量测序的精神分裂症患者肠道菌群多样性 被引量:11

Gut microbial profile analysis by high-throughput sequencing in schizophrenia patients
原文传递
导出
摘要 目的探讨精神分裂症患者肠道菌群多样性变化。方法收集16例精神分裂症患者(schizophrenia,Sch)与18例健康者(healthy donor,HD)的粪便样本,提取肠道菌群基因组,扩增16SrRNA基因,运用Illumina平台进行测序。对测序结果进行多样性和物种组成差异分析。结果精神分裂症患者组肠道菌群在门、纲、目、科、属、种、分类操作单元(operational taxonomic units,OTUs)水平的群落种类数目少于健康对照组。Alpha多样性指标中患者组的Ace指数(226.58±31.67)、Chao1指数(222.29±34.45)和Shannon指数(2.66±0.69)明显低于健康对照组(293.63±56.07、302.2±57.99、3.59±0.36),差异均有统计学意义(Ps<0.001),而Simpson指数(0.20±0.17)明显高于健康对照组(0.07±0.03),差异有统计学意义(P<0.01);Beta多样性分析显示两组研究对象肠道菌群样本可被鉴别区分。精神分裂症患者组与健康对照组样本在门和属水平上肠道菌群组成和含量有差异,其中患者组拟杆菌门和软壁菌门占比明显低于健康组,差异有统计学意义(21.76%vs.27.05%,P=0.008;0.00%vs.0.20%,P=0.033),而放线菌门明显高于健康组(13.52%vs.2.88%,P=0.020),差异有统计学意义;患者组拟杆菌属和柔嫩梭菌属占比明显低于健康组(9.15%vs.20.60%,P=0.031;3.29%vs.9.58%,P=0.005),差异有统计学意义,而双歧杆菌属、普雷沃菌属和巨单胞菌属明显高于健康组(10.89%vs.1.78%,P=0.025;10.88%vs.1.98%,P=0.046;10.78%vs.2.69%,P=0.026),差异有统计学意义。结论基于16SrRNA的高通量测序有助于分析精神分裂症患者肠道菌群多样性变化,为研究肠道菌群与精神分裂症的关系提供新的思路和理论依据。 Objective To explore the changes of gut microbiota in patients with schizophrenia.Methods Fresh fecal samples were collected from schizophrenia patients(n=16)and healthy controls(n=18)for DNA extraction,16 SrRNA amplification and Illumina sequencing.Analyses of diversity and species differences between two groups were based on the sequencing data.Results Compared to the healthy controls,the gut microbiota species in schizophrenia patients decreased at the levels of phylum,class,order,family,genus,species and operational taxonomic units(OTUs).The Ace estimator,Chao1 estimator and Shannon index of alpha diversity were significantly lower in schizophrenia patients(226.58±31.67,222.29±34.45,2.66±0.69)compared with the healthy controls(293.63±56.07,302.2±57.99,3.59±0.36,Ps<0.001),while the Simpson index was significantly higher(0.20±0.17 vs 0.07±0.03,P<0.01).Analyses ofβ-diversity was able to differentiate the schizophrenia patients from the healthy controls based on their gut microbiota.The compositions and proportions of gut microbiota in the schizophrenia group were different from those in controls at the levels of phylum and genus.At phylum level,Bacteroidetes and Tenericutes significantly reduced in schizophrenia patients compared to healthy controls(21.76%vs.27.05%,P=0.008;0.00%vs.0.20%,P=0.033),while Actinobacteria increased in schizophrenia patients compared to healthy controls(13.52%vs.2.88%,P=0.020).The genus Bacteroides and genus Faecalibacteriumsignificantly decreased in schizophrenia patients compared with the healthy controls(9.15% vs.20.60%,P=0.031;3.29%vs.9.58%,P=0.005),whereas genus Bifidobacterium,genus Prevotella-9and genus Megamonas significantly increased in schizophrenia patients compared with the healthy controls(10.89% vs.1.78%,P=0.025;10.88% vs.1.98%,P=0.046;10.78% vs.2.69%,P=0.026).Conclusion High-throughput sequencing of 16 SRNA is conducive to analysis of gut microbiota diversity,which can provide new ideas and theoretical foundations for studies on the relationship between gut microbiota and schizophrenia.
作者 赵星梅 王喜苹 周火祥 张红梅 王秀丽 罗予 郭葳 ZHAO Xingmei;WANG Xiping;ZHOU Huoxiang;ZHANG Hongmei;WANG Xiuli;LUO Yu;GUO Wei(Department of Psychiatry,the Eighth People′s Hospital of Zhengzhou,Zhengzhou,He′nan 450052,China)
出处 《中国微生态学杂志》 CAS CSCD 2019年第1期1-7,共7页 Chinese Journal of Microecology
基金 河南省科技攻关计划(172102310174) 河南省高等学校重点科研项目(18B310008)
关键词 精神分裂症 16S RRNA 肠道菌群 多样性 Schizophrenia 16S rRNA Gut microbiota Diversity
  • 相关文献

参考文献9

二级参考文献52

  • 1Kilbourne AM,Morden NE,Austin K,et al.Excess heart-disease-related mortality in a national study of patients with mental disorders:identifying modifiable risk factors[J].Gen Hosp Psychiatry,2009,31(6):555-563.
  • 2WHO.Global health risks:mortality and burden of disease attributable to selected major risks[S].Geneva:World Health Organization,2009.
  • 3Beary M,Hodgson R,Wildgust HJ.A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia:clinical and research implications[J].Journal of Psychopharmacology,2012,26(Suppl):52-61.
  • 4Kiviniemi M,Suvisaari J,Pirkola S,et al.Regional differences in five-year mortality after a first episode of schizophrenia in Finland[J].Psychiatr Serv,2010,61(3):272-279.
  • 5Kurihara T,Kato M,Reverger R,et al.Seventeen-year clinical outcome of schizophrenia in Bali[J].Eur Psychiatry,2011,26(5):333-338.
  • 6Mc Evoy JP,Lieberman JA,Perkins DO,et al.Efficacy and tolerability of olanzapine,quetiapine,and risperidone in the treatment of early psychosis:a randomized,double-blind 52-week comparison[J].Am J Psychiatry,2007,164(7):1050-1060.
  • 7Nasrallah HA,Meyer JM,Goff DC,et al.Low rates of treatment for hypertension,dyslipidemia and diabetes in schizophrenia:data from the CATIE schizophrenia trial sample at baseline[J].Schizophr Res,2006,86(1/3):15-22.
  • 8Kang JH,Xirisagar S,Lin HC.Lower mortality among stroke patients with schizophrenia:a nationwide population-based study[J].Psychosom Med,2011,73(1):106-111.
  • 9Kisely S,Campbell LA,Wang Y.Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare[J].Br J Psychiatry,2009,195(6):545-550.
  • 10Kelly DL,Mc Mahon RP,Wehring HJ,et al.Cigarette smoking and mortality risk in people with schizophrenia[J].Schizophr Bull,2011,37(4):832-838.

共引文献175

同被引文献95

引证文献11

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部